Many preclinical studies have shown high expression levels of TUBB3 are associated with paclitaxel resistance in human lung cancer [23], ovarian cancer [22], prostate cancer [24] and breast cancer [25] cell lines. This evidence concerns the gene TUBB3 and breast cancer.